Kendra Perry, NP
Primary Care · Pella, IANPI 1275247736
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $368 of the $468 with a category attached, or 78.7%. Sun Pharmaceutical Industries Inc. accounts for 65.5% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $290, more than ten times the $16 reported in 2023.
Across 15 payments — averaging $31.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$307
- Organon$39
- Pfizer$26
- Sumitomo Pharma America, Inc.$24
- Coopersurgical, Inc.$22
- Bayer$19
- plus $30 from 2 others
What the payments were for
- Food & beverage$36879%
- Education$10021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 7 | $307 |
| Organon | 2 | $39 |
| Pfizer | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Coopersurgical, Inc. | 1 | $22 |
| Bayer | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| Mayne Pharma Commercial LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILUMYA$123
How this compares
$468 in reported general payments places this provider in the 55th percentile of 36 primary care providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluocinonide | 90 | $2,764 |
| Metronidazole | 18 | $2,227 |
| Clobetasol Propionate | 33 | $1,829 |
| Ketoconazole | 64 | $691 |
| Minocycline Hcl | 31 | $573 |
| NyamycNystatin | 14 | $388 |
| MethotrexateMethotrexate Sodium | 26 | $322 |
| Terbinafine Hcl | 13 | $64 |
| Hydroxyzine Hcl | 13 | $53 |
| Triamcinolone Acetonide | 11 | $35 |
| Prednisone | 16 | $33 |
Paid to pharmacies, not to this prescriber.
Other primary care in Pella
- Emily WickhamCouncil Bluffs$7K
- Erin SwailesHiawatha$4K
- Jessica OgdenNewton$2K
- Jody HorstmanWest Des Moines$2K
- Chimene CobbLenox$2K
- Mary PedersenJefferson$1K
- Jamie HicksMilford$847
- Jennifer BlaylockAnkeny$787
- Catherine VailCouncil Bluffs$748
- Jennifer HutchinsonWest Union$664
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.